Nordic Issuing

Ongoing case

Prostatype Genomics AB

Back to all cases

Prostatype Genomics AB

9 Mar - 30 Mar 2023Warrant exercise TO 2

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype.

By providing a comprehensive assessment of prostate cancer aggressiveness, Prostatype helps doctors and patients make correct treatment decisions. Over- and under-treatment of prostate cancer can be minimized, the quality of life for the patient is improved and money can be saved for healthcare.

Read more at the company's website

The offer in summary

Subscription period: 9 March- 30 March 2023

Price per share: SEK 2.90

Trading with warrants: Until the 28th of March, 2023.

Payment day: 30 March 2023

Market place: First North Stockholm

Financial advicer: Sedermera Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.